In the TME, αPFC MBs were hydrolyzed, then CPT and FUDR were further released at a fixed 1:1 molar ratio to induce immunogenic cell death (ICD) to enhance anti-tumor efficacy, while the anti-PD-L1 antibody could block the PD-L1 receptor on the tumor cells to promote cytotoxic T Cell (CTL) infiltration, and thus achieve robust therapeutic effects and reduce the irAEs. This evidence concerns the gene CD274 and neoplasm.